However, it has been reported that 5%–10% of APL patients will relapse within the first 3 years.20 Since AGT has been shown to induce a high rate of apoptosis in HL60 cells, a promyelocytic leukemia cell line, it may have the potential to achieve clinical efficacy on APL patients. The gene discussed is AGT; the disease is acute promyelocytic leukemia.